- Home
- HCM vs VKTX Comparison
HCM vs VKTX Comparison
Compare HCM & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- VKTX
- Stock Information
- Founded
- HCM 2000
- VKTX 2012
- Country
- HCM Hong Kong
- VKTX United States
- Employees
- HCM N/A
- VKTX N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HCM Health Care
- VKTX Health Care
- Exchange
- HCM Nasdaq
- VKTX Nasdaq
- Market Cap
- HCM 2.5B
- VKTX 2.8B
- IPO Year
- HCM N/A
- VKTX 2015
- Fundamental
- Price
- HCM $14.21
- VKTX $27.55
- Analyst Decision
- HCM Hold
- VKTX Buy
- Analyst Count
- HCM 1
- VKTX 12
- Target Price
- HCM $19.00
- VKTX $84.00
- AVG Volume (30 Days)
- HCM 82.7K
- VKTX 4.3M
- Earning Date
- HCM 03-19-2025
- VKTX 04-23-2025
- Dividend Yield
- HCM N/A
- VKTX N/A
- EPS Growth
- HCM N/A
- VKTX N/A
- EPS
- HCM 0.04
- VKTX N/A
- Revenue
- HCM $630,201,000.00
- VKTX N/A
- Revenue This Year
- HCM $14.86
- VKTX N/A
- Revenue Next Year
- HCM $19.54
- VKTX N/A
- P/E Ratio
- HCM $68.70
- VKTX N/A
- Revenue Growth
- HCM N/A
- VKTX N/A
- 52 Week Low
- HCM $11.51
- VKTX $18.92
- 52 Week High
- HCM $21.92
- VKTX $81.81
- Technical
- Relative Strength Index (RSI)
- HCM 45.83
- VKTX 53.68
- Support Level
- HCM $14.18
- VKTX $26.37
- Resistance Level
- HCM $14.84
- VKTX $30.28
- Average True Range (ATR)
- HCM 0.57
- VKTX 1.65
- MACD
- HCM -0.03
- VKTX 0.27
- Stochastic Oscillator
- HCM 1.94
- VKTX 56.53
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.